Actively Recruiting
Phase 1 Study to Evaluate Safety and Effects of Single and Multiple Doses of MT-251 in Healthy Adults Aged 19 to 55
Led by Mirador Therapeutics, Inc. · Updated on 2026-02-25
70
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What this Trial Is About
Researchers are studying MT-251, a new biologic drug, in healthy adults aged 19 to 55 to evaluate its safety, tolerability, how the body processes it, and its immune response. This Phase 1, randomized, double-blind, placebo-controlled trial aims to gather important information to guide further development of MT-251. Participants will receive either single or multiple doses of MT-251 given by intravenous or subcutaneous injection. The study has two parts one to assess single ascending doses and another to assess multiple ascending doses, both closely monitored to evaluate safety and tolerability. During the study, participants will be monitored for side effects up to 14 days after dosing. Researchers will conduct health assessments and collect data to understand how MT-251 behaves in the body and its impact on the immune system. The study involves healthy volunteers and includes careful follow-up to ensure participant safety and gather necessary pharmacokinetic and immunogenicity information.
CONDITIONS
Brief Title
A First-in-Human Single and Multiple Ascending Dose Study of MT-251
Research Team
T
Toll-Free Number
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
